Literature DB >> 15264867

A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets.

Willem J M Mulder1, Gustav J Strijkers, Arjan W Griffioen, Louis van Bloois, Grietje Molema, Gert Storm, Gerben A Koning, Klaas Nicolay.   

Abstract

Pegylated paramagnetic and fluorescent immunoliposomes were designed to enable the parallel detection of the induced expression of molecular markers on endothelial cells with magnetic resonance imaging (MRI) and fluorescence microscopy. MRI is capable of three-dimensional noninvasive imaging of opaque tissues at near cellular resolution, while fluorescence microscopy can be used to investigate processes at the subcellular level. As a model for the expression of a molecular marker, human umbilical vein endothelial cells (HUVEC) were treated with the pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) to upregulate the expression of the adhesion molecule E-selectin/CD62E. E-selectin-expressing HUVEC were incubated with pegylated paramagnetic fluorescently labeled liposomes carrying anti-E-selectin monoclonal antibody as a targeting ligand. Both MRI and fluorescence microscopy revealed the specific association of the liposomal MR contrast agent with stimulated HUVEC. This study suggests that this newly developed system may serve as a useful diagnostic tool to investigate pathological processes in vivo with MRI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264867     DOI: 10.1021/bc049949r

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  44 in total

1.  Nanodiscs as a Modular Platform for Multimodal MR-Optical Imaging.

Authors:  Christiane E Carney; Ivan L Lenov; Catherine J Baker; Keith W MacRenaris; Amanda L Eckermann; Stephen G Sligar; Thomas J Meade
Journal:  Bioconjug Chem       Date:  2015-04-09       Impact factor: 4.774

2.  Relaxivity of liposomal paramagnetic MRI contrast agents.

Authors:  G J Strijkers; W J M Mulder; R B van Heeswijk; P M Frederik; P Bomans; P C M M Magusin; K Nicolay
Journal:  MAGMA       Date:  2005-09-09       Impact factor: 2.310

3.  MRI stem cell tracking for therapy in experimental cerebral ischemia.

Authors:  Pedro Ramos-Cabrer; Mathias Hoehn
Journal:  Transl Stroke Res       Date:  2011-10-27       Impact factor: 6.829

Review 4.  Liposomes in diagnosis and treatment of cardiovascular disorders.

Authors:  Tatyana S Levchenko; William C Hartner; Vladimir P Torchilin
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01

Review 5.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound.

Authors:  Ayele H Negussie; Pavel S Yarmolenko; Ari Partanen; Ashish Ranjan; Genevieve Jacobs; David Woods; Henry Bryant; David Thomasson; Mark W Dewhirst; Bradford J Wood; Matthew R Dreher
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 7.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 8.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

Review 9.  Paramagnetic liposome nanoparticles for cellular and tumour imaging.

Authors:  Nazila Kamaly; Andrew D Miller
Journal:  Int J Mol Sci       Date:  2010-04-15       Impact factor: 5.923

10.  New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.

Authors:  Ketan B Ghaghada; Murali Ravoori; Divya Sabapathy; James Bankson; Vikas Kundra; Ananth Annapragada
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.